CD1D and neoplasm: Additionally, they provide the rationale for using unmodified iNKT and checkpoint inhibitor combinations, even in CD1d-negative cancers, as an adjuvant strategy to overcome T and NK cell exhaustion and transform the TME into an immunologically “hot” ecosystem that supports continued tumor recognition and killing by endogenous cytotoxic cells.